Addex Changes Name to Addex Therapeutics, Launches New Website and Corporate Branding
(Thomson Reuters ONE) -
Addex Pharmaceuticals /
Addex Changes Name to Addex Therapeutics, Launches New Website and Corporate
Branding
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Geneva, Switzerland, 21 March 2012 - Addex Pharmaceuticals (SIX:ADXN), a leading
company pioneering allosteric modulation-based drug discovery and development,
announced today that it has changed its name to Addex Therapeutics. The name
change reflects more closely the company's focus on oral small molecule-based
therapeutics. Addex's ticker symbol on the Swiss Stock Exchange remains
unchanged at ADXN.
Alongside the name change, Addex has revealed a new logo and website. The icon
in the logo represents two things: the letter "X" from the Addex name and a
receptor bound by a natural ligand or cell signaling molecule in the active
site, depicted in blue, and an allosteric modulator bound to an allosteric site,
in orange.
Addex has also introduced a new tag line: "expanding the realm of possible."
which is literally what the allosteric approach is doing for drug discovery.
When applied to drug discovery, allostery offers the unique possibility of
developing oral small molecule drugs for targets that were previously considered
"undruggable" with conventional drug discovery approaches. Addex technology,
therefore, expands the realm of druggable targets.
The new website providesinformation on the company's strategy, pipelineand the
allosteric modulation-based drug discovery and development technology platform.
The new website also provides helpful information on the stock, corporate
governance and corporate calendar featuring the company's investor, media and
scientific outreach activities.
This name change is subject to shareholder approval.
Addex Therapeutics (www.addextherapeutics.com) discovers and develops an
emerging class of small molecule drugs, called allosteric modulators, which have
the potential to be more specific and confer significant therapeutic advantages
over conventional "orthosteric" small molecule or biological drugs. The Company
uses its proprietary discovery platform to address receptors and other proteins
that are recognized as attractive targets for modulation of important diseases
with unmet medical needs. The Company's two lead products are being investigated
in Phase IIa clinical testing: dipraglurant (ADX48621, an mGluR5 negative
allosteric modulator or NAM) is being developed by Addex to treat Parkinson's
disease levodopa-induced dyskinesia (PD-LID); and ADX71149 (mGluR2 positive
allosteric modulator or PAM) is being developed by our partner Janssen
Pharmaceuticals Inc. to treat schizophrenia. Addex also is advancing several
preclinical programs including: GABA-BR PAM for pain, overactive bladder and
other disorders; mGluR4 PAM for Parkinson's, anxiety and other diseases; GLP1R
PAM for type 2 diabetes; mGluR2 NAM for treating Alzheimer's disease and
depression; and FSHR/LHR NAM for sex hormone dependent tumors & reproductive
system disorders. In addition, Addex has discovery programs to identify
allosteric modulators of: receptor tyrosine kinase superfamily, including TrkB
PAM for treating neurodegenerative diseases (e.g. Alzheimer's, Parkinson's and
Huntington's diseases); and TNF receptor superfamily, including TNFR1 NAM for
inflammation (e.g. rheumatoid arthritis) and other diseases.
Chris Maggos
Business Development & Communication
Addex Therapeutics
+41 22 884 15 11
chris.maggos(at)addextherapeutics.com
Disclaimer: The foregoing release may contain forward-looking statements that
can be identified by terminology such as "not approvable", "continue",
"believes", "believe", "will", "remained open to exploring", "would", "could",
or similar expressions, or by express or implied discussions regarding Addex
Therapeutics Ltd, its business, the potential approval of its products by
regulatory authorities, or regarding potential future revenues from such
products. Such forward-looking statements reflect the current views of Addex
Therapeutics Ltd regarding future events, future economic performance or
prospects, and, by their very nature, involve inherent risks and uncertainties,
both general and specific, whether known or unknown, and/or any other factor
that may materially differ from the plans, objectives, expectations, estimates
and intentions expressed or implied in such forward-looking statements. Such may
in particular cause actual results with allosteric modulators of mGluR2, mGluR4,
mGluR5, GABABR, FSHR/LHR, GLP1R, TNFR1, RTK, TrkB or other therapeutic targets
to be materially different from any future results, performance or achievements
expressed or implied by such statements. There can be no guarantee that
allosteric modulators of mGluR2, mGluR4, mGluR5, GABABR, FSHR/LHR, GLP1R, TNFR1,
RTK, TrkB or other therapeutics targets will be approved for sale in any market
or by any regulatory authority. Nor can there be any guarantee that allosteric
modulators of mGluR2, mGluR4, mGluR5, GABABR, FSHR/LHR, GLP1R, TNFR1, RTK,
TrkB or other therapeutic targets will achieve any particular levels of revenue
(if any) in the future. In particular, management's expectations regarding
allosteric modulators of mGluR2, mGluR4, mGluR5, GABABR, FSHR/LHR, GLP1R,
TNFR1, RTK, TrkB or other therapeutic targets could be affected by, among other
things, unexpected actions by our partners, unexpected regulatory actions or
delays or government regulation generally; unexpected clinical trial results,
including unexpected new clinical data and unexpected additional analysis of
existing clinical data; competition in general; government, industry and general
public pricing pressures; the company's ability to obtain or maintain patent or
other proprietary intellectual property protection. Should one or more of these
risks or uncertainties materialize, or should underlying assumptions prove
incorrect, actual results may vary materially from those anticipated, believed,
estimated or expected. Addex Therapeutics is providing the information in this
press release as of this date and does not undertake any obligation to update
any forward-looking statements contained in this press release as a result of
new information, future events or otherwise, except as may be required by
applicable laws.
pdf:
http://hugin.info/138017/R/1596016/502712.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Addex Pharmaceuticals via Thomson Reuters ONE
[HUG#1596016]
Unternehmensinformation / Kurzprofil:
Datum: 21.03.2012 - 07:30 Uhr
Sprache: Deutsch
News-ID 126850
Anzahl Zeichen: 7742
contact information:
Town:
Plan-les-Ouates, Geneva
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 171 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Addex Changes Name to Addex Therapeutics, Launches New Website and Corporate Branding"
steht unter der journalistisch-redaktionellen Verantwortung von
Addex Pharmaceuticals (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
